Table 2 The association between MMR immunophenotype with clinicopathological factors in I-type tumors, PB-type tumors, and the entire cohort respectively
Intestinal type | Pancreatobiliary type | All | |||||||
|---|---|---|---|---|---|---|---|---|---|
pMMR (n = 50) | dMMR (n = 13) | p | pMMR (n = 102) | dMMR (n = 7) | p | pMMR (n = 152) | dMMR (n = 20) | p | |
Age | |||||||||
(Median, range) | 66.5 (38.0–79.0) | 67.0 (48.0–83.0) | 0.905 | 67.0 (44.0–81.0) | 62.0 (58.0–76.0) | 0.669 | 67.0 (38.0–81.0) | 65.5 (48.0–83.0) | 0.635 |
Sex | |||||||||
Women | 26 (52.0) | 8 (61.5) | 0.539 | 46 (45.1) | 4 (57.1) | 0.538 | 72 (47.4) | 12 (60.0) | 0.289 |
Men | 24 (48.0) | 5 (38.5) | 56 (54.9) | 3 (42.9) | 80 (52.6) | 8 (40.0) | |||
Tumor origin | |||||||||
Duodenum | 8 (16.0) | 6 (46.2) | 0.005 | 8 (5.3) | 6 (28.6) | 0.003 | |||
Ampulla intestinal type | 42 (84.0) | 7 (53.8) | 42 (27.6) | 7 (35.0) | |||||
Ampulla pancreatobiliary type | 17 (16.7) | 2 (28.6) | 0.860 | 17 (11.2) | 2 (10.0) | ||||
Distal bile duct | 44 (43.1) | 1 (14.3) | 44 (28.9) | 1 (5.0) | |||||
Pancreas | 41 (40.2) | 4 (57.1) | 41 (27.0) | 4 (20.0) | |||||
Tumor size mm | |||||||||
(Median, range) | 25.0 (5.0–60.0) | 40.0 (13.0–90.0) | 0.006 | 30.0 (9.0–70.0) | 30.0 (5.0–35.0) | 0.283 | 30.0 (5.0–70.0) | 33.0 (5.0–90.0) | 0.107 |
Differentiation grade | |||||||||
Well-moderate | 24 (48.0) | 7 (53.8) | 0.707 | 37 (36.3) | 4 (57.1) | 0.272 | 61 (40.1) | 11 (55.0) | 0.206 |
Poor | 26 (52.0) | 6 (46.2) | 65 (63.7) | 3 (42.9) | 91 (59.9) | 9 (45.0) | |||
T-stage | |||||||||
T1 | 4 (8.0) | 0 | 0.736 | 2 (2.0) | 0 | 0.966 | 6 (3.9) | 0 | 0.420 |
T2 | 9 (18.0) | 2 (15.4) | 11 (10.8) | 1 (14.3) | 20 (13.2) | 3 (15.0) | |||
T3 | 19 (38.0) | 6 (46.2) | 73 (71.6) | 5 (71.4) | 92 (60.5) | 11 (55.0) | |||
T4 | 18 (36.0) | 5 (38.5) | 16 (15.7) | 1 (14.3) | 34 (22.4) | 6 (30.0) | |||
N-stage | |||||||||
N0 | 24 (48.0) | 9 (69.2) | 0.348 | 26 (25.5) | 6 (85.7) | 0.002 | 50 (32.9) | 15 (75.0) | 0.002 |
N1 | 17 (34.0) | 2 (15.4) | 44 (43.1) | 1 (14.3) | 61 (40.1) | 3 (15.0) | |||
N2 | 9 (18.0) | 2 (15.4) | 32 (31.4) | 0 | 41 (27.0) | 2 (10.0) | |||
Margins | |||||||||
R0 | 13 (26.0) | 4 (30.8) | 0.730 | 6 (5.9) | 0 | 0.511 | 19 (12.5) | 4 (20.0) | 0.356 |
R1–Rx | 37 (74.0) | 9 (69.2) | 96 (94.1) | 7 (100.0) | 133 (87.5) | 16 (80.0) | |||
Perineural growth | |||||||||
No | 33 (66.0) | 11 (84.6) | 0.193 | 21 (20.6) | 3 (42.9) | 0.171 | 54 (35.5) | 14 (70.0) | 0.003 |
Yes | 17 (34.0) | 2 (15.4) | 81 (79.4) | 4 (57.1) | 98 (64.5) | 6 (30.0) | |||
Invasion of lymphatic vessels | |||||||||
No | 18 (36.0) | 11 (84.6) | 0.002 | 29 (28.4) | 5 (71.4) | 0.018 | 47 (30.9) | 16 (80.0) | 0.000 |
Yes | 32 (64.0) | 2 (15.4) | 72 (71.6) | 2 (28.6) | 105 (69.1) | 4 (20.0) | |||
Invasion of blood vessels | |||||||||
No | 45 (90.0) | 13 (100.0) | 0.235 | 67 (65.7) | 5 (71.4) | 0.757 | 112 (73.7) | 18 (90.0) | 0.111 |
Yes | 5 (10.0) | 0 | 35 (3437) | 2 (28.6) | 40 (26.3) | 2 (10.0) | |||
Growth in peripancreatic fat | |||||||||
No | 31 (62.0) | 10 (76.9) | 0.315 | 20 (19.6) | 4 (57.1) | 0.021 | 51 (33.6) | 14 (70.0) | 0.002 |
Yes | 19 (38.0) | 3 (23.1) | 82 (80.4) | 3 (42.9) | 101 (66.4) | 6 (30.0) | |||
Adjuvant chemotherapy | |||||||||
None | 35 (70.0) | 10 (76.9) | 0.094 | 46 (45.1) | 4 (57.1) | 0.177 | 81 (53.3) | 14 (70.0) | 0.040 |
5FU-analogue | 5 (10.0) | 0 | 8 (7.8) | 0 | 13 (8.6) | 0 (0.0) | |||
Gemcitabine | 7 (14.0) | 0 | 43 (42.2) | 2 (28.6) | 50 (32.9) | 2 (10.0) | |||
Gemcitabine + capecitabine | 0 | 1 (7.7) | 3 (2.9) | 0 | 3 (2.0) | 1 (5.0) | |||
Oxaliplatin + 5-FU analogue | 2 (4.0) | 2 (15.4) | 1 (1.0) | 0 | 3 (2.0) | 2 (10.0) | |||
Gemcitabine + oxaliplatin | 1 (2.0) | 0 | 1 (1.0) | 1 (12.5) | 2 (1.3) | 1 (5.0) | |||
Immune cells | |||||||||
CD3+ | 206 (6–795) | 246 (59–559) | 0.156 | 129 (22–546) | 44 (26–695) | 0.092 | 148.5 (6–795) | 227 (26–695) | 0.471 |
Missing | 0 | 0 | 0 | 0 | 0 | 0 | |||
CD8+ | 55 (2–180) | 114 (2–180) | 0.012 | 45 (4–175) | 37 (1–200) | 0.844 | 47.5 (2–180) | 101.5 (1–200) | 0.035 |
Missing | 1 | 0 | 3 | 0 | 4 | 0 | |||
FOXP3+ | 33 (0–110) | 40 (1–103) | 0.497 | 26 (1–137) | 15 (0–119) | 0.420 | 27.5 (0–137) | 38 (0–119) | 0.560 |
Missing | 0 | 0 | 2 | 1 | 2 | 1 | |||
CD68+ | 87 (29–350) | 74 (19–182) | 0.490 | 98 (25–230) | 97 (36–230) | 0.645 | 93 (25–350) | 82 (19–229) | 0.455 |
Missing | 0 | 0 | 1 | 1 | 1 | 1 | |||
CD163+ | 130 (35–250) | 120 (44–190) | 0.755 | 140 (49–275) | 162 (92–200) | 0.241 | 136 (35–275) | 131 (44–200) | 0.885 |
Missing | 1 | 0 | 4 | 1 | 5 | 1 | |||
CD56+ | 1 (0–9) | 2 (0–23) | 0.370 | 1 (0–12) | 3 (0–33) | 0.046 | 1 (0–12) | 2 (0–33) | 0.029 |
Missing | 0 | 0 | 0 | 0 | 0 | 0 | |||